Policy & Regulation
Kantaro Biosciences signs marketing agreement for COVID-SeroKlir and COVID-SeroIndex with EKF Diagnostics
29 October 2020 -

Kantaro Biosciences LLC and its manufacturing partner Bio -Techne Corporation (NASDAQ:TECH ) on Wednesday entered into a two-year marketing and distribution agreement of its COVID-SeroKlir and COVID-SeroIndex with EKF Diagnostics, a diagnostic company.

The agreement follows the CE Mark certification for the use of both COVID-SeroKlir and COVID-SeroIndex to detect the presence and precise titer (level) of IgG antibodies that a person produces as part of their immune response to exposure to the COVID-19 virus.

Under the terms of the agreement, EKF will offer the COVID-SeroKlir, which is Kantaro's SARS-CoV-2 IgG Quantitative Antibody Test Kit, in Europe with exclusive rights in the UK and Germany.

In conjunction with the agreement, EKF to offer Kantaro's COVID-SeroIndex for the European research market on a non-exclusive basis.

Both COVID-SeroKlir and COVID-SeroIndex have demonstrated a sensitivity of 97.8% and a specificity of 99.6% for detecting COVID-19 specific IgG antibodies. Its high precision results uses the two virus antigens: the full-length spike protein and its receptor-binding domain (RBD). The COVID-SeroKlir is configured to be more useful in a clinical setting, while the COVID-SeroIndex configuration is designed to aid research efforts and support policy formulation both in Europe and around the world, concluded the company.